Navigation Links
Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
Date:5/5/2009

ROCKVILLE, Md., May 5 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today the start of its Phase 1B trial for SQ109 with the dosing of the first cohort of volunteers. SQ109, a new diamine antibiotic intended to replace one or more of the current first-line antitubercular drugs and simplify patient therapy, was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows superior antibacterial activity against drug sensitive and both multi-drug resistant and extensively-drug resistant (MDR and XDR) Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). The Phase 1B study will assess safety, pharmacokinetics and tolerability of multiple ascending doses of SQ109 in three cohorts of healthy volunteers.

"We are pleased to begin this Phase 1B safety trial and to continue the clinical development of SQ109, a potentially valuable new drug candidate for the treatment of both uncomplicated and drug resistant TB," said Dr. Carol Nacy, Sequella CEO. "With the growing number of new TB cases within HIV-infected populations, there is no time to waste. Clinicians and patients alike are desperate for new drugs to shorten treatment times and improve patient outcomes. In a global world, the safety assessment of a new drug candidate with the antitubercular properties of SQ109 is an important milestone for patients on every continent, including North America."

The SQ109 Phase 1B trial is being conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), through a contract awarded to Dynport Corporation. The investigative site is the Quintiles Phase 1 facility in Overland Park, Kansas.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializin
'/>"/>

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
2. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
3. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
4. Psylin Neurosciences Commences Development of Compound for Depression
5. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
6. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
7. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
8. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
9. SenesTech, Inc. Commences Product Registration Process With Australian Government
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
(Date:9/18/2014)... , Sept. 18, 2014 About POCT ... is performed outside a clinical laboratory. It helps ... administrating appropriate treatments and medication. POCT is gaining ... of lifestyle diseases such as diabetes, heart disease, ... POCT devices are standardized to minimize errors during ...
(Date:9/18/2014)... Texas Governor Rick Perry, Texas ... Health Science Center CEO Brett Giroir, M.D., and ... Human Services (HHS), State of Texas and biopharmaceutical ... vaccine manufacturing facility in Bryan, Texas, which when ... Texas A&M Biocorridor – a rapidly evolving hub ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... VANCOUVER , July 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ... quarter ended June 30, 2010 . , ... "We are pleased to report continued quarter over quarter ... Products," said Dr. William Hunter , President and CEO of Angiotech. ...
... lend materials new characteristics are generally complicated and therefore ... to astonishment when scientists report on new methods which ... they use economically priced starting materials but also do ... framework made of polystyrene This is exactly ...
... Inc. (Nasdaq: MYL ) today announced that it intends to ... senior notes through a reopening of its Senior Notes due 2020, ... as additional notes under an existing indenture under which Mylan issued ... 2020 on May 19, 2010 . The notes to be ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 2Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 3Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 4Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 5Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 6Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 7Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 8Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 9Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 10Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 11Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 12Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 13Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 14Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 15Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 16Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 17Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 18Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 19Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 20Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 21Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 22Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 23Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 24Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 25Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 26Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 27Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 28Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 29Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 30Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 31Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 32Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 33Empa grows 'sea urchin'-shaped structures 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 3
(Date:9/18/2014)... deep in the primitive brainstem has revealed how we ... School of Medicine and the University at Buffalo School ... second "sleep node" identified in the mammalian brain whose ... produce deep sleep. , Published online in August in ... half of all of the brain,s sleep-promoting activity originates ...
(Date:9/18/2014)... Space Station ever starts a "frequent flyers" program, fruit ... the orbiting laboratory has hosted increasing numbers of fruit ... the space station in April, and another is scheduled ... is planned to launch in December. , Fruit flies ... world-- and in space. Model organisms can reveal the ...
(Date:9/18/2014)... their colleagues have built the first smartphone app ... and behavioral trends. In other words, your smartphone ... you don,t -- and how that affects you. ... stress, depression and loneliness to their academic performance, ... for example, to monitor mental health, trigger ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4
... , This news release is available in ... songbirds learn their songs from an adult model, mostly from the ... these songs are copied. Researchers from the Max Planck Institute for ... mechanism that is responsible for the differences in the intensity of ...
... Increasing awareness of biometrics across industries will spur ... adoption of biometrics has been concentrated in the ... for applications such as ATMs, retail points of ... have undergone substantial advancements and are gaining prominence, ...
... scientists are working to determine how neurons are generated, ... like Tuberous Sclerosis Complex (TSC). TSC is a ... in the brain and other vital organs and may ... that may arise from the abnormal generation of neurons. ...
Cached Biology News:Super song learners 2Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 2Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 3Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 4Clemson University study points to possible treatment for brain disorders 2
... (rEK) is a highly purified preparation of ... serine protease which recognizes the identical cleavage ... has similar enzymatic activity (1). Novagen&'s enzyme ... to yield the highest activity available, and ...
... benefits of a Hybridizer and UV Crosslinker (254nm ... , This unique, new design for ... at one location , Hybridizer and Crosslinker ... other , The Crosslinker is also available ...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... high performance spectral scanning multimode reader ... the advanced SkanIt Software it offers ... discovery assay development. Varioskan provides unlimited ... fluorescence and photometric assays and a ...
Biology Products: